Legato Capital Management LLC Trims Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Legato Capital Management LLC decreased its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 23.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 114,820 shares of the biopharmaceutical company’s stock after selling 34,695 shares during the period. Legato Capital Management LLC’s holdings in Ocular Therapeutix were worth $981,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in shares of Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after purchasing an additional 660,080 shares in the last quarter. Patient Square Capital LP bought a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at approximately $2,049,000. Polar Asset Management Partners Inc. bought a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at approximately $4,288,000. SG Americas Securities LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth approximately $393,000. Finally, FMR LLC lifted its stake in shares of Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after acquiring an additional 428,335 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Stock Up 0.4 %

Shares of Ocular Therapeutix stock opened at $7.48 on Friday. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -5.67 and a beta of 1.22. The firm’s 50-day moving average is $8.35 and its two-hundred day moving average is $8.99. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the transaction, the insider now directly owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Donald Notman sold 6,301 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the transaction, the insider now directly owns 204,563 shares of the company’s stock, valued at $1,603,773.92. The trade was a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,368 shares of company stock valued at $162,801. 3.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.